» Articles » PMID: 22670061

Impaired Blood Pressure Variability in Chronic Fatigue Syndrome--a Potential Biomarker

Overview
Journal QJM
Specialty General Medicine
Date 2012 Jun 7
PMID 22670061
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Autonomic dysfunction is common in chronic fatigue syndrome (CFS). This study set out to derive an autonomic biomarker using a comprehensive assessment of heart rate and blood pressure variability.

Methods: Heart rate and non-invasive continuous blood pressure measurements (task force monitor) at rest and on standing were performed in CFS (Fukuda n = 68) and matched controls (n = 68) to derive high frequency (HF; parasympathetic) and low frequency (LF; sympathetic) heart rate variability (HRV), systolic (SBPV) and diastolic (DBPV) blood pressure variability. Variables of significance were combined using receiver operator curves to explore the diagnostic utility of parameters particularly at rest.

Results: At rest, LF-HRV (sympathetic) was significantly increased in CFS compared to controls, while parasympathetic markers were significantly reduced (P = 0.006). Total DBP spectral power was increased (P = 0.0003) across all domains, with a shift towards sympathetic and away from parasympathetic SBPV (P = 0.05). On standing, overall SBPV response was significantly reduced with reductions in both sympathetic and parasympathetic components of SBPV (all P < 0.0001). Change in LF-DBP and relative balance of LF/HF DBP on standing differed between CFS and controls (P < 0.0001). Using the 85% sensitivity levels, we determined a threshold for three chosen resting BPV parameters of LF DBP >3.185, rest HF DBP >0.86, rest total DBP >7.05. Achieving all of these differentiated between CFS and controls with 77% sensitivity and 53% specificity.

Conclusion: This study has shown that there are objectively measured abnormalities of blood pressure variability in CFS and that these abnormalities have the potential to be a bedside diagnostic tool.

Citing Articles

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: the biology of a neglected disease.

Arron H, Marsh B, Kell D, Khan M, Jaeger B, Pretorius E Front Immunol. 2024; 15:1386607.

PMID: 38887284 PMC: 11180809. DOI: 10.3389/fimmu.2024.1386607.


Similar Patterns of Dysautonomia in Myalgic Encephalomyelitis/Chronic Fatigue and Post-COVID-19 Syndromes.

Ryabkova V, Rubinskiy A, Marchenko V, Trofimov V, Churilov L Pathophysiology. 2024; 31(1):1-17.

PMID: 38251045 PMC: 10801610. DOI: 10.3390/pathophysiology31010001.


Biomarkers for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a systematic review.

Maksoud R, Magawa C, Eaton-Fitch N, Thapaliya K, Marshall-Gradisnik S BMC Med. 2023; 21(1):189.

PMID: 37226227 PMC: 10206551. DOI: 10.1186/s12916-023-02893-9.


The Pathobiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Case for Neuroglial Failure.

Renz-Polster H, Tremblay M, Bienzle D, Fischer J Front Cell Neurosci. 2022; 16:888232.

PMID: 35614970 PMC: 9124899. DOI: 10.3389/fncel.2022.888232.


Brainstem Abnormalities in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Scoping Review and Evaluation of Magnetic Resonance Imaging Findings.

Nelson T, Zhang L, Guo H, Nacul L, Song X Front Neurol. 2022; 12:769511.

PMID: 34975729 PMC: 8718708. DOI: 10.3389/fneur.2021.769511.